ArticleFrontiers in immunology2025
Prediction of first-line immunotherapy response in patients with extensive-stage small cell lung cancer using a clinical-radiomics combined model.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A predictive model for immunotherapy in extensive-stage small cell lung cancer based on peripheral blood.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to explore the value of clinical-radiomics features for predicting response to immunotherapy in extensive-stage small cell lung cancer (ES-SCLC). Methods: This retrospective study enrolled patients with ES-SCLC who received immunotherapy as first-line treatment from two centers. Patients were divided into a training and an external test cohort. Chest Computed Tomography (CT) images were obtained at baseline and after 2-3 cycles of immunotherapy. Each lesion was segmented based on intratumoral regions (ITR) in the plain scan (PS) and venous phase (VP) CT images. Radiomic features, including absolute and relative delta features were extracted. Four signatures were established by the least absolute shrinkage and selection operator (LASSO) after selecting relevant features. Multivariable logistic regression incorporating signature scores and clinical predictors was used to generate a nomogram. The performance of the nomogram was evaluated through area under the curves (AUC) analysis, calibration curves, and decision curve analysis (DCA). Tertiary lymphoid structures (TLS) and the tumor immune microenvironment (TIME) of tumors were investigated via multiplex immunohistochemistry (mIHC). Kaplan-Meier curves were constructed to illustrate Overall Survival (OS) in different patients groups. Results: The nomogram was built based on two radiomics signatures (ITR before treatment; relative delta radiomics) and two clinical factors (age; node). This model showed powerful predictive ability for both training and external test sets with AUCs of 0.919 and 0.839, respectively. Calibration curves and DCA showed a favorable predictive performance of the nomogram. Conclusion: The nomogram that included ITR, delta radiomic features, and clinical risk factors had the best performance in predicting prognosis for patients with ES-SCLC who received immunotherapy compared to models relying solely on radiomic features or clinical risk factors, and has the potential to assist clinicians in making personalized treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.